Superintendency of Health Services approved the maximum reimbursement values for trastuzumab and bevacizumab, among other drugs and therapies
29 diciembre 2021
ARGENTINA
On December 29, the Superintendency of Health Services approved the maximum reimbursement values for a group of drugs, among which Trastuzumab and Bevacizumab stand out. These values will be applicable to reimbursement requests whose benefits have been provided as of January 1, 2022.
In the grounds for the measure, the Superintendency points out that through the Single Reimbursement System (SUR in Spanish) “pathologies of low incidence and high economic impact that represent those commonly known as catastrophic diseases, and those of prolonged treatment, thus catalogued due to the high impact they entail because of the heavy outlay they imply for those who finance them, are financially attended”.